CytoMed Therapeutics Limited (NASDAQ: GDTC) shares are witnessing a remarkable 19.42% surge in pre-market trading, climbing to $4.12. This significant uptick in GDTC stock followed the announcement of a pivotal collaboration agreement, positioning the company for promising advancements in cancer immunotherapy.
Groundbreaking Partnership with SunAct Cancer Institute
In order to investigate the therapeutic potential of CytoMed’s proprietary allogeneic gamma delta T cells, the company announced its signing of a Business & Research Collaboration Agreement (BRCA) with Mumbai-based SunAct Cancer Institute Private Limited, a well-known oncology-focused organization in India.
The collaboration includes a clinical research initiative, including a combined Phase 1 and Phase 2 investigator-led trial in India to evaluate the safety, tolerability, and effectiveness of these cells in treating various cancers, especially solid tumors.
The clinical trial will be jointly sponsored by CytoMed and SunAct, leveraging the expertise of SunAct’s medical team under the leadership of Dr. Vijay Patil, a distinguished oncologist and immunotherapy expert. In order to pave the way for revolutionary developments in cancer therapy, this expedited research project aims to determine the ideal dosage and assess preliminary safety and effectiveness characteristics.
Inexpensive Cancer Care in India
The partnership supports SunAct’s objective to provide affordable cancer treatments to a larger population in India, where cancer is a major burden. This collaboration aims to address both efficacy and affordability by utilizing the immune system’s capabilities to provide alternative treatment choices for a variety of solid malignancies.
This effort is further strengthened by the Central Drugs Standard Control Organization’s (CDSCO) favorable regulatory environment in India. The goal of financial incentives, like funding for cancer research, is to lower the costs of clinical research while promoting immunotherapy innovation.
Leveraging Complementary Strengths
Under the BRCA, CytoMed will provide scientific expertise, technical support, and manufacturing capabilities for the investigational product. The collaboration taps into SunAct’s local knowledge of regulations, healthcare infrastructure, and patient demographics, creating a synergistic pathway to develop advanced cell-based allogeneic immunotherapies.
This partnership underscores CytoMed’s (GDTC) commitment to delivering affordable, off-the-shelf immunotherapies, potentially transforming cancer care and improving the quality of life for patients worldwide.